We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy


Our medical oncologists and laboratory investigators are regular speakers and organizers of some of the most important international seminars and scientific meetings.

We have presented the results of our investigations into the causes of cancer and novel treatments at some of the most important national and international oncology congresses.


5th International Symposium on Novel Anticancer Agents for Practicing Oncologists


PLACEMadrid, Spain

Update on targeted therapies and non-small cell lung cancer Rosell R

XXXVI Lección Memorial Fundación Fernández Cruz


PLACEMadrid, Spain

European Society of Medical Oncology (ESMO)

DATE08/09/2017 - 12/09/2017

PLACEMadrid, Spain

Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

Solange Peters, Tony Mok, Alice T. Shaw, Dong-Wan Kim, Sai-Hong Ignatius Ou, Maurice Pérol, Rafal Dziadziuszko, Jin Seok Ahn, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Eveline Nueesch, Bogdana Balas, D. Ross Camidge
A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors
M. Gonzalez-Cao, J. Martinez- Picado, M. Provencio, B. Clotet, O. Juan, J. Dalmau, T. Moran, A. Meyerhans, J. de Castro, J. Blanco, R. Bernabe, N. Karachaliou, J. Garcia-Corbacho, R. Blanco, C. Brander, J. Carrillo, MA. Molina, R. Rosell

A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
S. Postel-Vinay, D. Planchard, A.L. Ortega Granados, A. Gazzah, M.A. Sala Gonzalez,
M. Majem, C.J. Camps, A. Abou-Lauvergne, J-P. Pignon, J. Cadranel, J. Bennouna,
F. Barlesi, M.R. Garcia Campelo, S. Viteri, B. Besse, J. Coves Sarto, B. Massuti
Sureda, J-C. Soria, R. Rosell

Intracranial Efficacy of Brigatinib (BRG) in Patients (Pts) With Crizotinib (CRZ)-Refractory Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC) and Baseline CNS Metastases
Sai-Hong Ignatius Ou, Marcello Tiseo, D Ross Camidge, Myung-Ju Ahn, Rudolf M Huber, Maximilian J Hochmair, Sang-We Kim, Howard L West, Karen L Reckamp, Julian R Molina, Geoffrey Liu, Angelo Delmonte, Santiago Viteri, Alessandra Bearz, Yvonne Summers, William Reichmann, David Kerstein, Scott N Gettinger, Dong-Wan Kim

ONCOS-102 and pemetrexed/cisplatin in patients with unresectable
malignant pleural mesothelioma

S. Ponce Aix, S. Viteri, J. Bosch-Borrera, L. Kuryk, T. Hakonen, S. Vetrhus,
M. Jaderberg, L. Paz-Ares

Brigatinib in Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC): Long-term Efficacy and Safety Results From a Phase 1/2 Trial
Lyudmila A Bazhenova, Scott N Gettinger, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Jeff Haney, Victor M Rivera, David Kerstein, D Ross Camidge
Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)
R. Palmero, A. Taus, M. Majem Tarruella, S. Viteri, E. Carcereny Costa, J. Garde,
E. Felip Font, C. Cassidy, D. Dix, N. Karachaliou, R. Rosell

Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
J.M. Trigo Perez, E. van Brummelen, E. Levchenko, M. Domine Gomez, D.A. Fennell, H.L. Kindler, S. Viteri, S. Gadgeel, P. Garrido Lopez, V. Kostorov, D. Morgensztern, S. Orlov, P.K. Paik, J.F. Vansteenkiste, X. Wang, A. Sharabidze, M.P. Deyoung, K.P. Baker, L. Yan, I. Mitrica

Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC
S. Calabuig Farinas, E. Jantus-Lewintre, A. Fernandez, C. Mayo de las Casas,
A. Blasco, C. Aguilar, N. Jordana, A. Balada, M. Garzon Ibanez, F. Zhang, N. Dong, M.A. Molina, R. Rosell, C. Camps Herrero

Annual Meeting, American Society of Clinical Oncology (ASCO)

DATE02/06/2017 - 06/06/2017


Alectinib vs. crizotinib  in ALK+ NSCLC (ALEX study)

Alice T. Shaw, Solange Peters, Tony Mok, Shirish M. Gadgeel, Jin Seok Ahn, Sai-Hong Ignatius Ou, Maurice Perol, Rafal Dziadziuszko, Dong-Wan Kim, Rafael Rosell, Ali Hassan Zeaiter, Ting Liu, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, D. Ross Camidge
[return] Dacomitinib vs. gefitinib in EGFR mutant NSCLC (ARCHER 1050)
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Rolf Linke, Eric Sbar, Tao Wang, Yi-Long Wu

Phase 1/2 Study of Veliparib (V) Combined With Carboplatin (Cb) and Etoposide (E) in Patients (pts) With Extensive-stage Disease (ED) Small Cell Lung Cancer (SCLC) and Other Solid Tumors: Phase 1 Results
Florence Atrafi, Harry J. M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep S. Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Y. Gabrail, Tina Waskiewicz, Beibei Hu, Tu Xu, Hao Xiong, Elizabeth Hoening, Philip Komarnitsky, Antonio Calles

Interferon-gamma, a marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients
Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowsky, Ana Gimenez-Capitan, Cristina Teixidó, Miguel Angel Molina, Santiago Viteri, Daniela Morales, María de los Llanos Gil, María González Cao, Salvador Martín Algarra, Elisabeth Pérez-Ruiz, Iván Márquez-Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puértolas, María Angeles Royo, Rafael Rosell

HIV as a model for understanding immuno-oncology


PLACEAuditorium, Dexeus University Hospital

The objective of this meeting is to bring together scientists who share a common interest in immunotherapy with the aim of fostering new interdisciplinary approaches and inspiring scientists and clinicians. The workshop will provide a space for professionals from different disciplines to interact and share experiences, learn about the latest research findings, develop novel hypotheses, and enhance insights into how to modulate the immune response.